Table 1. Clinical trials using radiation therapy specifically for non-small-cell lung cancer brain metastases.
| Study (year) | Phase | Patients (n) | RT modality | Additional therapies | BM (n) | OS (months) | Ref. |
|---|---|---|---|---|---|---|---|
| Dinglin et al. (2013) | II | 42 | WBRT | Pemetrexed + cisplatin | NA | 12.6 WBRT | [47] |
| Langley et al. (2013) | III | 151 | WBRT | OSC | NA | 49 days WBRT vs 51 days OSC | [96] |
| Sperduto et al. (2013) | III | 126 | WBRT + SRS | TMZ vs erlotinib | 1–3 | 13.4 WBRT + SRS vs 6.3 WBRT + SRS + TMZ vs 6.1 WBRT + SRS + erlotinib | [48] |
| Welsh et al. (2013) | II | 40 | WBRT | Erlotinib | NA | 11.8 WBRT | [49] |
| Pesce et al. (2012) | II | 59 | WBRT | Gefitinib or TMZ | NA | 4.9 WBRT | [50] |
| Galetta et al. (2011) | II | 29 | WBRT | Cisplatin + fotemustine | NA | 4.7† WBRT | [51] |
| Minnitti et al. (2010) | – | 66 | WBRT + SRS | NA | 2–3 | 10.3 WBRT + SRS vs 7.2 WBRT | [61] |
| Chua et al. (2010) | II | 95 | WBRT | TMZ | NA | 4.4 WBRT + TMZ vs 5.7 WBRT | [52] |
| Quantin et al. (2010) | II | 70 | WBRT | Cisplatin + vinorelbine + ifosfamide vs HD ifosfamide | NA | 8.5 WBRT + cisplatin + vinorelbine + ifosfomide vs 5.7 WBRT + HD ifosphamide | [53] |
| Mehta et al. (2009) | III | 554 | WBRT | Motexafin gadolinium | NA | NA | [63] |
| Neuhaus et al. (2009) | III | 70 | WBRT | Topotecan | NA | NA | [54] |
| Lind et al. (2009) | I | 11 | WBRT | Erlotinib | NA | 133 days WBRT | [55] |
| Ma et al. (2009) | II | 21 | WBRT | Gefitinib | NA | 13.0 WBRT | [56] |
| Huang et al. (2007) | I | 16 | WBRT | Gemcitabine | NA | NA | [57] |
| Guerrieri et al. (2004) | III | 42 | WBRT | Carboplatin | NA | 4.4 WBRT vs 3.7 WBRT + carboplatin | [58] |
| Robinet et al. (2001) | III | 176 | WBRT (early vs delayed) | Cisplatin + vinorelbine | NA | 24 weeks cisplatin + vinorelbine + delayed WBRT vs 21 weeks cisplatin + vinorelbine + early WBRT | [59] |
| Bogart et al. (1999) | – | 15 | I125 brachytherapy | Surgery | 1 | 14 I125 brachytherapy | [62] |
| Pronzato et al. (1995) | – | 20 | WBRT | Carboplatin + teniposide | NA | 7 WBRT | [60] |
| Chatani et al. (1994) | – | 162 | WBRT | NA | NA | 5.4 WBRT (30 Gy) in subjects with normal LDH vs 4.8 WBRT (50 Gy) in subjects with normal LDH vs 3.4 WBRT (30 Gy) in subjects with high LDH vs 2.4 WBRT (20 Gy) in subjects with high LDH | [97] |
†Estimated.
BM: Brain metastases; HD: High dose; LDH: Lactate dehydrogenase; NA: Not applicable; OS: Overall survival; OSC: Optimal supportive care; RT: Radiation therapy; SRS: Stereotactic radiosurgery; TMZ: Temozolomide; WBRT: Whole-brain radiation therapy.